Literature DB >> 2479412

Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities.

Y Igarashi1, S Hakomori, T Toyokuni, B Dean, S Fujita, M Sugimoto, T Ogawa, K el-Ghendy, E Racker.   

Abstract

In view of the possible effects of the sphingoid base on protein kinases, and the fact that the sphingoid bases used in previous studies were not chemically well-defined, we have studied the effects of chemically well-defined sphingosines and their derivatives on kinase activity. Both (4E)-D- and (4E)-L-erythro-sphingenine showed a weak inhibitory effect, and (4E)-L-threo-sphingenine had a moderate inhibitory effect. In contrast, (4E)-N,N-dimethyl-D-erythro-sphingenine and the sphingosine preparation from a commercial source showed a strong inhibitory effect on PK-C in A431 cells as well as on purified PK-C. Synthetic (4E)-D-erythro-sphingenine and several samples of natural sphingosine inhibited v-src or c-src tyrosine kinase activity measured with polyglutamate-tyrosine (4:1) as substrate. N-Acetylated or N-methylated sphingosines did not inhibit src kinase activity, but rather produced a consistent 1.5-2-fold stimulation of such activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479412     DOI: 10.1021/bi00443a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  44 in total

1.  Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells.

Authors:  D O'Byrne; D Sansom
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

2.  Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.

Authors:  Mithun R Raje; Kenneth Knott; Yugesh Kharel; Philippe Bissel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2011-11-15       Impact factor: 3.641

3.  A novel sphingosine kinase inhibitor induces autophagy in tumor cells.

Authors:  Vladimir Beljanski; Christian Knaak; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2010-02-23       Impact factor: 4.030

4.  Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Authors:  Yanjun Shi; Hasibur Rehman; Venkat K Ramshesh; Justin Schwartz; Qinlong Liu; Yasodha Krishnasamy; Xun Zhang; John J Lemasters; Charles D Smith; Zhi Zhong
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

5.  Essential Role of Sphingosine Kinase 2 in the Regulation of Cargo Contents in the Exosomes from K562 Cells.

Authors:  Nesma Nabil Ibrahim Mohamed; Taro Okada; Taketoshi Kajimoto; Shun-Ichi Nakamura
Journal:  Kobe J Med Sci       Date:  2018-05-25

6.  Sphingosine kinase-mediated Ca2+ signalling by G-protein-coupled receptors.

Authors:  D Meyer zu Heringdorf; H Lass; R Alemany; K T Laser; E Neumann; C Zhang; M Schmidt; U Rauen; K H Jakobs; C J van Koppen
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

7.  Induction of neutrophil homotypic adhesion via sialophorin (CD43), a surface sialoglycoprotein restricted to haemopoietic cells.

Authors:  A R Rosenkranz; O Majdic; J Stöckl; W Pickl; H Stockinger; W Knapp
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

8.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

9.  Sphingosine-based liposome as DNA vector for intramuscular gene delivery.

Authors:  Karin Baraldo; Nicolas Leforestier; Michel Bureau; Nathalie Mignet; Daniel Scherman
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

10.  The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids.

Authors:  Subramaniam Ramachandran; Uyen B Chu; Timur A Mavlyutov; Arindam Pal; Susan Pyne; Arnold E Ruoho
Journal:  Eur J Pharmacol       Date:  2009-03-11       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.